Substance / Medication

Anidulafungin

Overview

Active Ingredient
anidulafungin
RxNorm CUI
341018
Labeler: RoerigUpdated: 2025-08-19T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

ERAXIS is contraindicated in: • Warnings and Precautions (5.2) [see] Patients with known hypersensitivity to anidulafungin, any component of ERAXIS, or other echinocandins • Warnings and Precautions (5.4) [see] Patients with known or suspected Hereditary Fructose Intolerance (HFI)

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

8 trials linked to this intervention

8
Total Trials
0
Recruiting
6
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
De Rosa Francesco Giuseppe, Busca Alessandro, Capparella Maria Rita et al. · Clin Drug Investig · 2021
PMID: 33891293Meta-AnalysisFull text (PMC)
Pharmacokinetics of anidulafungin in critically ill patients with candidemia/invasive candidiasis.
Liu Ping, Ruhnke Markus, Meersseman Wouter et al. · Antimicrob Agents Chemother · 2013
PMID: 23335738RCTFull text (PMC)
Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults.
Crandon Jared L, Banevicius Mary Anne, Fang Annie F et al. · Antimicrob Agents Chemother · 2009
PMID: 19770284RCTFull text (PMC)
Safety and pharmacokinetics of coadministered voriconazole and anidulafungin.
Dowell James A, Schranz Jennifer, Baruch Alice et al. · J Clin Pharmacol · 2005
PMID: 16291712RCT
Anidulafungin exposure and population pharmacokinetics in critically ill patients with invasive candidiasis.
Elkayal Omar, Hoffert Yannick, Mertens Beatrijs et al. · Infection · 2025
PMID: 39641856Observational
Evaluation of clinical outcomes of anidulafungin for the treatment of candidemia in hospitalized critically ill patients with obesity: A multicenter, retrospective cohort study.
Alsowaida Yazed Saleh, Sulaiman Khalid Al, Mahrous Ahmad J et al. · Int J Infect Dis · 2024
PMID: 39241957Observational
Pharmacokinetics of anidulafungin in critically ill patients with Candida peritonitis.
Pérez Civantos D V, Robles Marcos M, Azanza Perea J R et al. · Int J Infect Dis · 2019
PMID: 31330325Observational
A Comparative Study of the Effects of Intravitreal Anidulafungin, Voriconazole, and Amphotericin B in an Experimental Candida Endophthalmitis Model.
Karagoz Ergenekon, Ugan Rustem Anil, Duzgun Eyup et al. · Curr Eye Res · 2017
PMID: 27348425Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Anidulafungin (substance)
SNOMED CT
422157006
UMLS CUI
C1142738
RxNorm CUI
341018
Labeler
Roerig

Clinical Data

This intervention maps to 4 entities in the Healos knowledge graph.

4
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
8
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.